Oncological Outcomes of Neoadjuvant Chemotherapy in High‐Risk UTUC: A Multicenter Study

Oncological Outcomes and Safety Profiles of Adjuvant Nivolumab in Muscle‐Invasive Urothelial Carcinoma

Perioperative immunotherapy has become the standard of care in patients with high‐risk muscle‐invasive urothelial carcinoma (MIUC). This study aimed to clarify oncological outcomes and safety profiles of adjuvant nivolumab therapy in MIUC, focusing on upper tract urothelial carcinoma (UTUC).

Prognostic stratification of patients with biliary tract cancer treated with chemoimmunotherapy: A retrospective multicenter real‐world study

The objective of this study is to explore and validate a novel prognostic index for patients with locally advanced or metastatic biliary tract cancer (BTC) treated with first‐line therapy with cisplatin, gemcitabine, and durvalumab.

hiFU is safe, effective, and feasible in pancreatic cancer patients: a monocentric retrospective study among 523 patients

Five‐Year Survival Analyses on Non‐Pathological Complete Response Esophageal Squamous Cell Carcinoma Patients After Neoadjuvant Regimens Plus Surgery: A Propensity Score Matching, Real‐World Cohort Study

Non‐pathological complete response (non‐pCR) is common in esophageal squamous cell carcinoma (ESCC) patients after neoadjuvant therapy, yet evidence guiding long‐term outcomes and postoperative risk stratification in the immunotherapy era remains limited.

Long-Term Outcomes of De-Escalated 30-Gy Elective Irradiation in HPV-Associated Oropharyngeal Cancer.

This cohort study describes 5-year outcomes following a de-escalated 30-Gy elective nodal irradiation regimen during definitive concurrent chemoradiotherapy among patients with human papillomavirus–associated oropharyngeal carcinoma.

Neoadjuvant Nivolumab–Ipilimumab versus Platinum-Based Chemotherapy in Muscle-Invasive Bladder Cancer: A Single-Institution, Propensity-Weighted Cohort Study

Introduction: Neoadjuvant chemotherapy (NAC) is standard for muscle-invasive bladder cancer (MIBC), yet many patients are platinum-ineligible. We compared outcomes of neoadjuvant nivolumab plus ipilimumab versus platinum-based NAC